YU62096A - Kontrolisano-otpuštajuća farmaceutska formulacija, korišćenje polietilen oksida u njima i postupak za njihovu proizvodnju - Google Patents

Kontrolisano-otpuštajuća farmaceutska formulacija, korišćenje polietilen oksida u njima i postupak za njihovu proizvodnju

Info

Publication number
YU62096A
YU62096A YU62096A YU62096A YU62096A YU 62096 A YU62096 A YU 62096A YU 62096 A YU62096 A YU 62096A YU 62096 A YU62096 A YU 62096A YU 62096 A YU62096 A YU 62096A
Authority
YU
Yugoslavia
Prior art keywords
polyethylene oxide
procedure
preparation
application
pharmaceutical formulation
Prior art date
Application number
YU62096A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
Ross James Macrae
Janet Sarah Smith
Original Assignee
Pfizer Research And Development Company N.V./S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Research And Development Company N.V./S.A. filed Critical Pfizer Research And Development Company N.V./S.A.
Publication of YU62096A publication Critical patent/YU62096A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
YU62096A 1995-11-21 1996-11-20 Kontrolisano-otpuštajuća farmaceutska formulacija, korišćenje polietilen oksida u njima i postupak za njihovu proizvodnju YU62096A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9523752.5A GB9523752D0 (en) 1995-11-21 1995-11-21 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
YU62096A true YU62096A (sh) 1999-03-04

Family

ID=10784188

Family Applications (1)

Application Number Title Priority Date Filing Date
YU62096A YU62096A (sh) 1995-11-21 1996-11-20 Kontrolisano-otpuštajuća farmaceutska formulacija, korišćenje polietilen oksida u njima i postupak za njihovu proizvodnju

Country Status (29)

Country Link
EP (1) EP0862437A1 (fr)
JP (1) JPH10513481A (fr)
KR (1) KR19990071505A (fr)
CN (1) CN1215993A (fr)
AP (1) AP718A (fr)
AR (1) AR004335A1 (fr)
AU (1) AU709560B2 (fr)
BG (1) BG102438A (fr)
BR (1) BR9611626A (fr)
CA (1) CA2232715A1 (fr)
CO (1) CO4480020A1 (fr)
CZ (1) CZ155498A3 (fr)
GB (1) GB9523752D0 (fr)
HR (1) HRP960554A2 (fr)
HU (1) HUP9903734A3 (fr)
IS (1) IS4706A (fr)
MA (1) MA26410A1 (fr)
MX (1) MX9804008A (fr)
NO (1) NO982302L (fr)
NZ (1) NZ322053A (fr)
OA (1) OA10687A (fr)
PE (1) PE22898A1 (fr)
PL (1) PL326981A1 (fr)
SK (1) SK63098A3 (fr)
TN (1) TNSN96141A1 (fr)
TR (1) TR199800902T2 (fr)
WO (1) WO1997018814A1 (fr)
YU (1) YU62096A (fr)
ZA (1) ZA969722B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ504487A (en) * 1997-12-16 2002-11-26 Pfizer Prod Inc Combination of alpha-adrenergic antagonists and cGMP elevators for the treatment of impotence
BR9908911A (pt) 1998-03-19 2001-10-02 Bristol Myers Squibb Co Sistema bifásico e processo de distribuição por liberação controlada de substâncias farmacêuticas de alta solubilidade
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
EP0987020A1 (fr) * 1998-09-04 2000-03-22 Pharma Pass LLC Composition contenant du metoprolol et procédé de préparation
EP0974343B1 (fr) * 1998-07-22 2004-09-29 Pharma Pass II LLC Procédé de préparation d'une composition solide contentant du metoprolol
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US20030059467A1 (en) * 2001-09-14 2003-03-27 Pawan Seth Pharmaceutical composition comprising doxasozin
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2005037247A2 (fr) * 2003-10-17 2005-04-28 Ranbaxy Laboratories Limited Formulations matricielles de doxazosine a administration orale
US20050255157A1 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Sustained release, mucoadhesive vaginal pharmaceutical compositions
KR100574554B1 (ko) * 2004-05-28 2006-04-27 한미약품 주식회사 니아신의 경구투여용 서방성 조성물
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
KR100679111B1 (ko) * 2004-11-20 2007-02-07 대우약품공업주식회사 독사조신을 포함하는 서방성 정제
CA2619035A1 (fr) * 2005-08-22 2007-03-01 Novartis Ag Compositions pharmaceutiques
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
AU2007242984B2 (en) 2006-04-26 2012-11-08 Supernus Pharmaceuticals Inc. Controlled released preparations of oxcarbazepine having sigmoidal release profile
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
CA2810522A1 (fr) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Polymorphes
CN100396282C (zh) * 2006-07-25 2008-06-25 山东省医药工业研究所 甲磺酸多沙唑嗪缓释胶囊及制备方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
WO2009114648A1 (fr) 2008-03-11 2009-09-17 Depomed Inc. Formes médicamenteuses à libération étendue de rétention gastrique comprenant des combinaisons d'un analgésique non opioïde et d'un analgésique opioïde
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
PL2395983T3 (pl) 2009-02-13 2020-09-07 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna zawierająca inhibitor sglt2, inhibitor dpp-iv i ewentualnie dalszy środek przeciwcukrzycowy oraz jej zastosowania
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
BRPI1013856A2 (pt) 2009-04-20 2016-04-05 Elcelyx Therapeutics Inc terapias à base de ligantes de receptores quimiossensíveis
KR102668834B1 (ko) 2009-11-27 2024-05-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
JP6042330B2 (ja) 2010-07-09 2016-12-14 ビーエイチヴィ ファーマ、インコーポレイテッド レモグリフロジンを含めた半減期が短い医薬品のための組合せ即時／遅延放出送達システム
KR20140114736A (ko) 2010-10-19 2014-09-29 엘셀릭스 테라퓨틱스 인코포레이티드 화학감각 수용체 리간드-기반 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2012094636A2 (fr) 2011-01-07 2012-07-12 Elcelyx Therapeutics, Inc. Traitements à base de ligand de récepteur chimiosensoriel
CN102058555A (zh) * 2011-01-13 2011-05-18 北京汇诚瑞祥医药技术有限公司 一种多沙唑嗪控释片
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
CN102188431A (zh) * 2011-05-09 2011-09-21 浙江九旭药业有限公司 甲磺酸多沙唑嗪缓释片及其制备方法
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013158928A2 (fr) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Thérapies à base de ligand de récepteur chimiosensoriels
EP3685839A1 (fr) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin pour son utilisation dans le traitement de l'albuminurie et des maladies liees au rein
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
CN105431144A (zh) 2013-06-05 2016-03-23 思康脑侒股份有限公司 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
CN105616378A (zh) * 2014-10-31 2016-06-01 康普药业股份有限公司 一种氟康唑胶囊及其制备方法
MX2018015089A (es) 2016-06-10 2019-05-13 Boehringer Ingelheim Int Combinacion de linagliptina y metformina.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1198386B (it) * 1982-07-06 1988-12-21 Lepetit Spa Un prodotto a rilascio protratto contenente il suloctidile
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4837111A (en) * 1988-03-21 1989-06-06 Alza Corporation Dosage form for dispensing drug for human therapy
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
PT98374A (pt) * 1990-07-23 1994-01-31 Alza Corp Dispositivo osmotico para administracao sistemica de nicotina e processo nele baseado

Also Published As

Publication number Publication date
BR9611626A (pt) 1999-06-01
JPH10513481A (ja) 1998-12-22
CZ155498A3 (cs) 1999-03-17
IS4706A (is) 1998-03-31
CN1215993A (zh) 1999-05-05
WO1997018814A1 (fr) 1997-05-29
GB9523752D0 (en) 1996-01-24
MA26410A1 (fr) 2004-12-20
PL326981A1 (en) 1998-11-09
AU709560B2 (en) 1999-09-02
HUP9903734A3 (en) 2000-04-28
KR19990071505A (ko) 1999-09-27
AR004335A1 (es) 1998-11-04
TR199800902T2 (xx) 1998-09-21
AU7572196A (en) 1997-06-11
TNSN96141A1 (fr) 2005-03-15
SK63098A3 (en) 1999-05-07
NO982302L (no) 1998-07-17
ZA969722B (en) 1998-05-20
NO982302D0 (no) 1998-05-20
HUP9903734A2 (hu) 2000-03-28
HRP960554A2 (en) 1998-02-28
BG102438A (en) 1999-01-29
EP0862437A1 (fr) 1998-09-09
CA2232715A1 (fr) 1997-05-29
AP9600883A0 (en) 1997-01-31
NZ322053A (en) 1999-11-29
MX9804008A (es) 1998-09-30
OA10687A (en) 2002-11-27
PE22898A1 (es) 1998-05-07
CO4480020A1 (es) 1997-07-09
AP718A (en) 1999-01-06

Similar Documents

Publication Publication Date Title
YU62096A (sh) Kontrolisano-otpuštajuća farmaceutska formulacija, korišćenje polietilen oksida u njima i postupak za njihovu proizvodnju
YU49698A (sh) Smeše koje sadrže tetrahidrolipstatin
RS50303B (sr) Farmaceutska kompozicija nimesulida sa kontrolisanim oslobađanjem
DE60120648D1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
HUP0302319A2 (hu) Gyógyszerkészítmények gyógyászati hatóanyagok szájon át történő bejuttatására
AR023972A1 (es) Composiciones de medicamentos a base de compuestos anticolinergicamente activos y beta-mimeticos
RS50937B (sr) Farmaceutska kompozicija koja sadrži metformin i glibenklamid za lečenje šećerne bolesti tipa ii
HRP20020880B1 (en) New pharmaceutical composition
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
AR037260A1 (es) Formulaciones de proteinas de liberacion sostenida acuosas
HRP20020088B1 (en) Levodopa/carbidopa/entacapone pharmaceutical preparation
DE69520768D1 (de) Pharmazeutische Zubereitungen, die Fluoxetin enthalten
ME00330B (fr) Formulations d'oxycodone a administration quotidienne unique
ATE425744T1 (de) Pharmazeutische formulierungen mit verbesserter bioverfugbarkeit
ME00637B (fr) Compositions contenant des acides diphosphoniques
RS49890B (sr) Preparat u formi praška koji sadrži medicinsko sredstvo velike molekulske težine za primenu preko sluzokože
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
AR011919A1 (es) FORMULACIoN EN COMPRIMIDOS O CÁPSULAS PARA TRAGAR DE PARACETAMOL (N-ACETIL-P-AMINOFENOL) Y PROCEDIMIENTO PARA PREPARARLA
HUP0301390A2 (hu) Valzartánt tartalmazó orális gyógyászati készítmény
BR0115989A (pt) Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido
MY137570A (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis crohn's disease
SE0001916D0 (sv) Novel formulation
CA2255064A1 (fr) Formulations pharmaceutiques contenant du potassium, du sodium et des sels tris d'oxaprozine
HUP9901659A2 (hu) Flupirtin alkalmazása a hematopoetikus sejtrendszer károsodásával kapcsolatos megbetegedések megelőzésére és gyógyítására alkalmas gyógyszerkészítmény előállítására
YU82693A (sh) Farmaceutske formulacije disulfonil metana i novi disulfonil metani